Sexual health products tops in DTC-driven web traffic

Share this article:
NuvaRing and Latisse lead the pack in DTC-driven traffic to their sites, according to Manhattan Research.

The research firm's ePharma Consumer survey found that Merck Contraceptive NuvaRing jumped five spots to take the top spot for ad-driven traffic, while Allergan's eyelash-extender, Latisse, launched last year, placed second.  
Sexual health products dominated the top 10. Latisse was followed by Cialis, Boniva, Abilify, Gardasil, Yaz, Viagra, Levitra and Lunesta.

“These are things where talking to friends and family or doctors might be awkward, so they want to research it on their own,” said VP research Meredith Ressi, “and especially with the oral contraceptive category, that's a much younger segment and one that's very active online.”

Also common to the top 10 was full incorporation of the website into the broader ad campaign. “Latisse especially integrated the URL into their campaign,” said Ressi, noting that ads pointed viewers to the site for before and after photos of Brooke Shields' lashes, and to submit their own.

The study results will be the topic of a Manhattan Research webinar Thursday.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.